Alembic Crosses $250m Annual Sales In US

Company Plans 10 New Launches In First Half Of FY21

Reporting positive fourth-quarter results at the end of its financial year, Alembic says it has achieved a milestone of its US business passing annual sales of $250m.

Growth
Alembic sees unprecedented growth in its US business • Source: Shutterstock

India’s Alembic Pharmaceuticals says its US front-end business has passed the “milestone” of $250m in annual sales for its financial year ended 31 March 2020 after the business grew by more than half – 53% – to INR19.76bn ($263m), boosted by fourth-quarter growth of 84% to INR5.77bn.

Alembic credited its “well-established US front-end that has a strong customer base” that helped expand the company’s ability “to deliver...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business